gabaa-receptor-modulators
(2)
Newleos Therapeutics
Newleos Therapeutics is a Boston-based, clinical-stage biotechnology company building a new generation of treatments for neuropsychiatric disorders. Launched in February 2025 with an oversubscribed $93.5 million Series A, the company in-licensed four clinical-ready oral small molecules from Roche - targeting GABAA-y1, V1a, TAAR1, and GABAA-a5 - aimed at generalized anxiety, social anxiety, substance use disorders, and cognitive impairment. Its name nods to 'eos,' the Greek word for dawn: a new dawn for mental health treatment.
Timothy Noyes
Timothy Noyes is the President and CEO of Newleos Therapeutics, a Boston clinical-stage biotech that raised an oversubscribed $93.5M Series A to revive four neuropsychiatric compounds shelved by Roche. A Harvard-trained operator with three decades in biopharma, he has taken Proteon and Aerovate public, launched Renagel at GelTex/Genzyme, and built teams that carry molecules from bench to late-stage trials.